Navigation Links
Study examining large-scale data of double balloon enteroscopy shows it is safe and effective
Date:9/26/2011

OAK BROOK, Ill. Sept. 26, 2011 A large-scale data review by researchers in China of double balloon enteroscopy (DBE) over the last decade showed the endoscopic procedure to be safe and effective for detection of diseases of the small intestine. DBE had a pooled detection rate of 68.1 percent for all small intestinal disease. Suspected mid-gastrointestinal bleeding was found to be the most common indication, with a relatively high detection rate. Inflammatory lesions and vascular lesions were the most common findings in patients with suspected mid-gastrointestinal bleeding. The study appears in the September issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE).

Balloon assisted or "deep" enteroscopy is a procedure which can allow the advancement of a long endoscope (called an enteroscope) into the small intestine for both diagnostic and therapeutic purposes. Balloon assisted enteroscopy may use a one or two balloon system. The system using two balloons is called double balloon enteroscopy (DBE). The balloon assisted enteroscopy technique advances the endoscope through the small bowel by alternately inflating and deflating balloons, and pleating the small bowel over an insertion tube like a curtain over a rod. The procedure can be performed via the upper gastrointestinal (GI) tract (antegrade) or through the lower GI tract (retrograde).The procedure is indicated for patients who have problems in the small intestine including bleeding, strictures, abnormal tissue, polyps, or tumors. Since the first article introducing DBE was published in GIE: Gastrointestinal Endoscopy in 2001, DBE has been widely used in clinical practice worldwide.

Methods

Up until now, there have been many published original articles across the world addressing the technical aspects and positive findings of DBE. However, most of these studies were of small sample size and show inconsistent, if not controversial, data among different settings and in different countries. Therefore, the researchers performed this systematic review of all eligible studies related to diagnostic DBE during the decade of development in order to produce state-of-the-art data on indications, lesion detection rate, total enteroscopy, and complications in examining diseases of the small intestine.

The researchers, led by Zhuan Liao, MD, and Zhao-Shen Li, MD, Department of Internal Medicine, Changhai Hospital, Second Military Medical University, Shanghai, China, searched PubMed between January 1, 2001 and March 31, 2010 for original articles about DBE evaluation of diseases of the small intestine. Data on total number of procedures, distribution of indications, pooled detection rate, pooled total enteroscopy rate, and composition of positive findings were extracted and/or calculated. In addition, the data involving DBE-associated complications were analyzed. Indications were defined as the primary reasons for DBE. DBE findings that could explain the symptoms of the patient and resulted in a change in therapeutic management were considered positive findings, and these included any clinically significant findings in the entire GI tract. Total enteroscopy was defined when the entire small intestine was successfully visualized. Complications of DBE were defined as any adverse events that occurred during and after the procedures and were divided into minor and major categories. Minor complications included GI symptoms such as nausea, vomiting, abdominal distension, and other transient and self-limiting symptoms. Major complications included any severe adverse events that required hospitalization and/or an endoscopic or surgical intervention and/or contributed to the death of the patient.

Results

A total of 66 English-language original articles involving 12,823 procedures were included. Suspected mid-gastrointestinal bleeding was the most common indication (62.5 percent), followed by symptoms and signs only (7.9 percent), small intestine obstruction (5.8 percent), and Crohn's disease (5.8 percent). The pooled detection rates were as follows: suspected mid-gastrointestinal bleeding (68.1 percent), symptoms and signs only (68 percent), Crohn's disease (53.6 percent), and small intestine obstruction (63.4 percent). The overall detection rate was 85.8 percent. Inflammatory lesions (37.6 percent) and vascular lesions (65.9 percent) were the most common findings, respectively, in suspected mid-gastrointestinal bleeding patients of Eastern and Western countries. The pooled total enteroscopy rate was 44 percent by combined or antegrade-only approach. The pooled minor and major complication rates were 9.1 percent and 0.72 percent, respectively.

The researchers concluded that the detection rate and complication rate of DBE are acceptable. They found that DBE is a valuable modality, with a pooled detection rate of 68.1 percent for all small intestinal disease. Inflammatory lesions and vascular lesions are the most common findings in patients with suspected mid-gastrointestinal bleeding in Eastern and Western countries, respectively, according to DBE. Although DBE failed to identify a proportion of lesions, they consider that the performance of DBE is acceptable because the symptoms of a significant proportion of patients without positive findings would not recur during follow-up. They noted that DBE is considered to be a safe procedure with few complications, most of which are minor.

In an accompanying editorial, Andrew S. Ross, MD, Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Wash., stated, "we finally have composite large-scale data to support what we have suspected - DBE performed in appropriately selected individuals is a highly useful and extremely safe clinical tool that can be used for a variety of indications for deep enteroscopy. Although it is clearly an improvement over technologies of the past, DBE is not without its limitations and does not provide an answer in every patient. No amount of data can replace clinical vigilance and long-term follow-up. In the case of small-bowel disorders and obscure GI bleeding in particular, it is up to us as endoscopists to selectively choose from the now-myriad selection of devices within our toolbox that can help us to solve what is often a vexing clinical problem."


'/>"/>

Contact: Anne Brownsey
abrownsey@asge.org
630-570-5635
American Society for Gastrointestinal Endoscopy
Source:Eurekalert

Related medicine news :

1. Boston researchers share in $10 million grant to study HIV and alcohol
2. Cell Transplantation study shows bone growth from implanted tooth and dental pulp stem cells
3. Bone Drug Fails to Prevent Breast Cancer Recurrence: Study
4. Study shows decisions over life-sustaining treatment are likely to change
5. Non-verbal clues guide doctor-patient relationships, clinical judgments, U-M study finds
6. Antioxidants Not Behind Red Wines Healthy Effect on Heart: Study
7. Foam injections for varicose veins better for patients and cheaper, study finds
8. Study sheds light on the impact of COPD on working aged populations
9. Phase II study shows new cancer drug combination significantly delays breast cancer progression
10. NYU study finds congestion pricing works best when partnered with land-use planning
11. Wayne State University study aims to improve diabetes management in high-risk youth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash ... has enlisted New York City-based sports and entertainment marketing firm Leverage Agency as ... opportunities for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, ...
(Date:3/29/2017)... ... March 30, 2017 , ... Youth Futures International (YFI) premiered its ... from high school and college students who have participated in the program every summer. ... YFI is now accepting applications for enrollment. Visit http://www.ghana.yfiexperience.org to learn ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs sold ... in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these results ... in HeartBoost, an over the counter heart healthy drink, can reduce Arterial Plaque, ...
(Date:3/29/2017)... ... March 29, 2017 , ... Dr. Angela Cotey, a noted general ... accepting new pediatric patients, with or without a referral. Dr. Cotey knows that ... orthodontic outcome and experience. When patients receive early treatment, they may achieve straight teeth ...
(Date:3/29/2017)... ... ... Curio Wellness , a premium medical cannabis brand and trusted healthcare ... team with prominent executives from both inside and outside the cannabis industry. , ... Dumbauld , who has more than twenty years of business leadership and investment experience ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... March 29, 2017  Spiral Therapeutics, Inc. today ... Bionure Farma, S.L. for the worldwide exclusive rights ... in the field of otolaryngology for aggregate payments ... The agreement provides Spiral with the option ... differentiated product profile. Under the terms of the ...
(Date:3/29/2017)... , March 29, 2017   Royal ... leader in health technology, and PathAI, a company ... collaborating with the aim to develop solutions that ... of cancer and other diseases. The partnership aims ... enabling this form of artificial intelligence to be ...
(Date:3/29/2017)... , USA, March 29, 2017 Stryker ... that Cares by People magazine, in partnership with Great ... 50 companies on the list. This list highlights the ... have succeeded in business while also demonstrating respect, compassion ... environment.  To determine the companies on ...
Breaking Medicine Technology: